Updated Jul 16, 2026 · Last SEC filing 2026-07-09
IONIS PHARMACEUTICALS INC (IONS) has filed 27 SEC Form 4 insider transactions in the last 90 days, with the most recent on 2026-07-09. 8 Form 8-K material event filings were reported by IONS in the last 90 days. 14 Form 144 notices of proposed sale were filed for IONS stock. InsiderAlpha tracks every IONS SEC filing — Form 4, Form 144, and 8-K — in real time, including Rule 10b5-1 plan detection.
| SIC classification | Pharmaceutical Preparations (SIC 2834) |
|---|---|
| SEC CIK | 0000874015 |
| Form 4 filings (90d) | 27 |
|---|---|
| Form 8-K filings (90d) | 8 |
| Form 144 notices (90d) | 14 |
| Latest Form 4 filing | 2026-07-09 |
| Date | Insider | Role | Transaction | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| Diaz Allene M. | Director | S — Open-market sale | 10.1K | $85.42 | $864K | SEC | |
| Diaz Allene M. | Director | M — Option exercise | 10.1K | $47.11 | $476K | SEC | |
| BENNETT C FRANK | EVP, Chief Scientific Officer | S — Open-market sale | 5.5K | $83.58 | $463K | SEC | |
| BENNETT C FRANK | EVP, Chief Scientific Officer | J — Other acquisition / disposition | 15.0K | $0.00 | — | SEC | |
| BENNETT C FRANK | EVP, Chief Scientific Officer | S — Open-market sale | 15.0K | $85.46 | $1.28M | SEC | |
| Kordasiewicz Holly B. | EVP, Chief Development Officer | S — Open-market sale | 362 | $84.30 | $31K | SEC | |
| KLEIN JOSEPH III | Director | S — Open-market sale | 11.4K | $79.04 | $903K | SEC | |
| KLEIN JOSEPH III | Director | S — Open-market sale | 99 | $79.45 | $8K | SEC | |
| KLEIN JOSEPH III | Director | M — Option exercise | 11.5K | $39.94 | $460K | SEC | |
| Schneider Eugene | EVP, Chf Clinical Develop Ofcr | S — Open-market sale | 26.0K | $81.05 | $2.11M | SEC | |
| O'NEIL PATRICK R. | EVP CLO & General Counsel | S — Open-market sale | 3.1K | $80.00 | $246K | SEC | |
| Baroldi Joseph | EVP, Chief Business Officer | M — Option exercise | 3.9K | $56.78 | $220K | SEC | |
| Monia Brett P | Chief Executive Officer | M — Option exercise | 50.0K | $56.78 | $2.84M | SEC | |
| Schneider Eugene | EVP, Chf Clinical Develop Ofcr | M — Option exercise | 26.0K | $60.89 | $1.58M | SEC | |
| Baroldi Joseph | EVP, Chief Business Officer | M — Option exercise | 1.8K | $32.60 | $58K | SEC |
All transactions sourced from SEC EDGAR Form 4 filings for IONIS PHARMACEUTICALS INC (IONS). Updated in real time as new filings are submitted to the SEC.
| Insider | Form 4 filings | Total transaction value |
|---|---|---|
| LOSCALZO JOSEPH | 16 | $9.57M |
| Monia Brett P | 15 | $11.33M |
| Kordasiewicz Holly B. | 11 | $7.78M |
| KLEIN JOSEPH III | 10 | $2.59M |
| Baroldi Joseph | 8 | $1.15M |
Form 144 must be filed before insiders sell restricted or control stock above SEC thresholds. A cluster of Form 144 notices often precedes a wave of insider distribution.
SEC Form 4 transactions are reported with a one-letter code indicating the type of transaction. Common codes you'll see in IONS insider filings:
| P | Open-market purchase by the insider |
|---|---|
| S | Open-market sale by the insider |
| A | Grant, award, or other acquisition from the issuer |
| M | Exercise or conversion of derivative security (e.g. options) |
| F | Payment of exercise price or tax liability via share withholding |
| G | Bona-fide gift of securities |
| D | Disposition to the issuer (e.g. share buyback participation) |
| J | Other acquisition or disposition |
| X | Exercise of in-the-money or at-the-money derivative security |
| C | Conversion of derivative security |
| V | Transaction voluntarily reported earlier than required |
Open the live IONS dashboard on InsiderAlpha for real-time alerts, charting, and full historical filing search.